Changes of central macular thickness post intravitreal ranibizumab and its associated factors among diabetic macular oedema patients
Background: Intravitreal Ranibizumab (IVR) which is an anti-vascular endothelial growth factor (anti-VEGF) has become the preferred treatment option to improve the vision of diabetic macular oedema (DMO) patients. IVR acts by inhibits VEGF-A from binding to its receptors, leading to decreased in vas...
Saved in:
Main Author: | Tahir, Nursyafiqah Md |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2020
|
Subjects: | |
Online Access: | http://eprints.usm.my/51000/1/Nursyafiqah%20Md%20Tahir-24%20pages.pdf http://eprints.usm.my/51000/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy of intravitreal triamcinolone versus aser photocoagulation in the primary treament of diabetic macular oedema
by: Mustafa, Norlaili
Published: (2008) -
Evaluation of visual acuity and macular thickness post focal laser with and without supplementary honey in diabetic macular oedema
by: Rahim, Raihan Abd
Published: (2016) -
Agreement of macular oedema features between FFA And HRT II and evaluation of visual function, macular oedema index and quality of life post laser photocoagulation in diabetic macular oedema
by: Embong, Zunaina
Published: (2016) -
Prevalence and genetic analyses of selected age-related macular degeneration-related polymorphisms and their responses to intravitreal ranibizumab
by: Mohamad, Nur Afiqah
Published: (2018) -
Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects
by: Mohamad, Nur Afiqah, et al.
Published: (2019)